Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain
CD8+ cytotoxic T-cell responses during chronic viral infection.
J. Virol. 68, 8056–8063
et al. Enhanced establishment of a virus carrier state in adult CD4
+ T-cell-deficient mice. J. Virol. 68,
Rosenberg, E. S.
et al. Vigorous HIV-1-specific CD4+ T cell responses
associated with control of viremia. Science 278,
et al. Early highly active antiretroviral therapy for acute HIV-1
infection preserves immune function of CD8+ and CD4
+ T lymphocytes. Proc. Natl Acad. Sci. USA
97, 3382–3387 (2000).
et al. Effect of combination antiretroviral therapy on T-cell immunity
in acute human immunodeficiency virus type 1 infection. J. Infect.
Dis. 181, 121–131 (
Kalams, S. A. & Walker, B. D. The critical need for CD4 help
in maintaining effective cytotoxic T lymphocyte responses. J. Exp.
Med. 188, 2199–2204 (
von Herrath, M. G., Yokoyama, M., Dockter, J., Oldstone, M. B. & Whitton, J. L. CD4-deficient mice have reduced
levels of memory cytotoxic T lymphocytes after immunization and show diminished
resistance to subsequent virus challenge. J. Virol.
70, 1072–1079 (1996).
Zajac, A. J.
et al. Viral immune evasion due to persistence of activated T cells
without effector function. J. Exp. Med. 188,
Kalams, S. A.
et al. Association between virus-specific cytotoxic T-lymphocyte
and helper responses in human immunodeficiency virus type 1 infection.
J. Virol. 73, 6715–6720 (1999).
Gerlach, J. T.
et al. Recurrence of hepatitis C virus after loss of virus-specific
CD4(+) T- cell response in acute hepatitis C. Gastroenterology
117, 933–941 (
et al. Analysis of successful immune responses in persons infected
with hepatitis C virus. J. Exp. Med. 191,
et al. Control of HIV despite the discontinuation of antiretroviral
therapy. N. Engl. J. Med. 340, 1683–
Ortiz, G. M.
et al. HIV-1-specific immune responses in subjects who temporarily
contain virus replication after discontinuation of highly active antiretroviral
therapy. J. Clin. Invest. 104, R13–
Kahn, J. O. & Walker, B. D. Acute human immunodeficiency virus
type 1 infection. N. Engl. J. Med. 339,
Lori, F. et
al. Treatment of human immunodeficiency virus infection with hydroxyurea,
didanosine, and a protease inhibitor before seroconversion is associated with
normalized immune parameters and limited viral reservoir. J. Infect.
Dis. 180, 1827–1832 (
Carpenter, C. C.
et al. Antiretroviral therapy for HIV infection in 1997. Updated
recommendations of the International AIDS Society/USA panel. J.
Am. Med. Assoc. 277, 1962–1969
Lyles, R. H.
et al. Natural history of human immunodeficiency virus type 1 viremia
after seroconversion and proximal to AIDS in a large cohort of homosexual
men. Multicenter AIDS Cohort Study. J. Infect. Dis.
181, 872–880 (2000).
et al. Major expansion of CD8+ T cells with a predominant
V beta usage during the primary immune response to HIV. Nature
370, 463–467 (
et al. Positive effects of combined antiretroviral therapy on CD4
+ T cell homeostasis and function in advanced HIV disease.
Science 277, 112–116 (
Evans, D. T.
et al. Virus-specific cytotoxic T-lymphocyte responses select for
amino-acid variation in simian immunodeficiency virus Env and Nef.
Nature Med. 5, 1270–1276 (1999).
Dhodapkar, M. V.
et al. Rapid generation of broad T-cell immunity in humans after
a single injection of mature dendritic cells. J. Clin. Invest.
104, 173–180 (
Davey, R. T.Jr
et al. HIV-1 and T cell dynamics after interruption of highly active
antiretroviral therapy (HAART) in patients with a history of sustained viral
suppression. Proc. Natl Acad. Sci. USA 96,
Janssen, R. S.
et al. New testing strategy to detect early HIV-1 infection for use
in incidence estimates and for clinical and prevention purposes.
J. Am. Med. Assoc. 280, 42–48
Little, S. J.
et al. Reduced antiretroviral drug susceptibility among patients
with primary HIV infection. J. Am. Med. Assoc. 282,
Brander, C. & Walker, B. D. in Molecular Immunology Data Base
(eds Korber, B. T. et al.) IV-50–IV-60
(Los Alamos National Laboratory, Los Alamos, New Mexico,
Goulder, P. J.
et al. Differential narrow focusing of immunodominant human immunodeficiency
virus gag-specific cytotoxic T-lymphocyte responses in infected African and
caucasoid adults and children. J. Virol. 74,
Walker, B. D.
et al. Long-term culture and fine specificity of human cytotoxic
T-lymphocyte clones reactive with human immunodeficiency virus type 1.
Proc. Natl Acad. Sci. USA 86, 9514–
Martinez-Picado, J., Sutton, L., De Pasquale, M. P., Savara, A. V. & D'Aquila, R. T. Human immunodeficiency virus
type 1 cloning vectors for antiretroviral resistance testing.
J. Clin. Microbiol. 37, 2943–2951
Kalams, S. A.
et al. Levels of human immunodeficiency virus type 1-specific cytotoxic
T- lymphocyte effector and memory responses decline after suppression of viremia
with highly active antiretroviral therapy. J. Virol.
73, 6721–6728 (1999).